Analyst Ratings for Edgewise Therapeutics
Portfolio Pulse from Benzinga Insights
Edgewise Therapeutics (NASDAQ:EWTX) has received positive analyst ratings in the last quarter, with 4 bullish ratings and no bearish or indifferent ratings. The company's average 12-month price target is $25.25, which has increased by 1.0% over the past month.
June 27, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edgewise Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, the positive ratings for Edgewise Therapeutics indicate a bullish outlook, which could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100